Mike Derkacz

Proud father of 4 and CEO of @braeburnrx

[Mike Derkacz @mderkacz]

People with opioid use disorder deserve compassion, respect and access to multiple treatment options just like with other chronic diseases.
Congratulations to the Braeburn team for your role in reaching this important milestone: https://t.co/pWadbBuXOE

[Mike Derkacz @mderkacz]

What a week for Braeburn! I’m honored to see our latest news featured in Fierce Pharma "The Top Line" podcast, and so incredibly proud of my colleagues at Braeburn. https://t.co/GiZQ0LiFGB

See Full Prescribing Information with Boxed Warning: https://t.co/HTy6NWe5l5

[Mike Derkacz @mderkacz]

I am thrilled to announce this news related to Braeburn’s investigational medication for OUD. The resilience and commitment of our team has made this happen. https://t.co/1iZeT3a2K3

[Mike Derkacz @mderkacz]

A major step in the right direction to reduce barriers to treatment for opioid use disorder. https://t.co/3d2ty4LNv7

[Mike Derkacz @mderkacz]

We are pleased to announce that we have submitted our Request for Final Approval to FDA as the next step in our mission to fight the opioid crisis. https://t.co/9EvZkXrHxI

[Mike Derkacz @mderkacz]

"You have got to show up on time, and you have to know the text, and you have to have a head full of ideas.” I couldn’t agree more and am proud to work with a team that is accountable, prepared, willing to take risks and open to new ideas. https://t.co/QfuaHnaP3y

[Mike Derkacz @mderkacz]

Congratulations to our EU partner, Camurus, on the topline results announcement for their open-label study in patients with OUD. https://t.co/uH09aBdCaB

[Mike Derkacz @mderkacz]

We are dedicated to ensuring pts w/OUD can access all txs. "Orphan-designation for Indivior’s Sublocade (buprenorphine ER) was improperly granted 25yrs ago under Orphan Drug cost recovery provision & should be revoked, FDA said in 1st-of-kind decision." https://t.co/gw9IrNRJc2

[Mike Derkacz @mderkacz]

We are pleased to announce that FDA has granted our Citizen Petition and revoked orphan designation, enabling access to new treatments for patients with OUD. https://t.co/rnUtzuNTn7

[Mike Derkacz @mderkacz]

We are pleased by the District Court’s decision which is an important step toward making an additional treatment option available to healthcare providers and patients with opioid use disorder. https://t.co/Mqw8DmpYbF

[Mike Derkacz @mderkacz]

Recognizing the acute nature of opioid use disorder, hospitals may be the “missing link” in combatting this crisis. https://t.co/lWB5tRWeR8

[Mike Derkacz @mderkacz]

I am thrilled to be joining a panel of experts at #BIO2019 this afternoon to discuss creating a new paradigm to spur the development of treatments for those suffering from the devastation of addiction. @IAMBiotech.

[Mike Derkacz @mderkacz]

.@Braeburnrx is committed to delivering solutions for people living with the serious, often fatal consequences of opioid addiction. We are pleased to announce the publication of our Phase 3 open-label safety study in the treatment of opioid use disorder.

[Mike Derkacz @mderkacz]

A loophole in the Orphan Drug Act could prevent approval of new medications to treat opioid use disorder in the midst of a crisis that could spike to 250 deaths per day if access to treatment doesn’t improve. https://t.co/CMYoiyCtmo

[Braeburn @braeburnrx]

Representatives from #TeamBraeburn are attending #RxSummit2019 starting today to strengthen our collaboration with all stakeholders from government, healthcare, academia, law enforcement and caregivers to find solutions that address the US drug overdose crisis.

[Mike Derkacz @mderkacz]

Best practices discovered in these 4 states must be shared with communities across the country as quickly as possible. https://t.co/Vl6KU8D1wg

[Braeburn @braeburnrx]

At Braeburn, everything we think, say and do is with patients in mind. Filing this Petition was necessary to bring vital treatment options to patients suffering with #opioid #addiction as soon as possible. https://t.co/WefJHKdERr

[Mike Derkacz @mderkacz]

I am pleased to announce the positive post-hoc analyses results for a Phase 3 efficacy and safety study presented today at #ASAM2019. https://t.co/xK2jXrT8lH

[Mike Derkacz @mderkacz]

@ShatterproofHQ launched the #HopeStems campaign this week to reduce the stigma of medication treatment for opioid use disorder. https://t.co/DjlD6PNTdA

[Mike Derkacz @mderkacz]

@ShatterproofHQ launched the #HopeStems campaign this week to reduce the stigma of medication treatment for opioid use disorder. https://t.co/DjlD6PNTdA